Guidance on reducing heterogeneity and improving robustness in multi-national, database studies.
Background Multi‐national/database pharmacoepidemiological studies are increasingly used to address questions that require pooled evidence across populations but introduce challenges in design, harmonization, and analysis. Objective To share 10 practical considerations and common pitfalls in planning, executing, and reporting multi‐national/database studies, with strategies to mitigate them. Approach Practical guidance article synthesizing experience from multi‐national/database projects and literature‐based exemplars; no original data collection. Results We summarize ten considerations spanning: protocol development; follow‐up time and eligibility assessment; data harmonization (including thorough metadata and master mapping tables); feasibility checks within each source; statistical model diagnostics; and transparent reporting. We illustrate how local clinical practices, coding systems, and reimbursement policies can shape outcomes and interpretation, and we emphasize the need for proactive, consistent communication among collaborators to ensure aligned implementation. Conclusion Multi‐national/database studies are complex but feasible with structured planning, clear communication, and proactive problem‐solving. Adopting the outlined practices can reduce avoidable heterogeneity and improve the robustness and interpretability of findings.
No takes yet. Share an insight, caveat, or question.
Man et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: